SCR-LIP-000162 · Claim · machine-readable JSON →

In a 10-year retrospective before-and-after study, lymph-sparing multistage liposuction (median 3 sessions, mean total 17,887 ml aspirated) produced durable improvements, with a median 37.5% reduction in conservative-therapy (CDT) score, 25.5% of patients discontinuing all conservative treatment, and significant VAS symptom reductions; outcomes were better in earlier stages (I+II) and in patients aged <41 years with BMI ≤35 kg/m².

Claim at a glance
Type
clinical association
Knowledge state
Emerging
Evidence certainty
low (GRADE)
Evidence
3 source(s)
Dates
2026-05-31 → 2026-06-12

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

2022Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis — Ghods et al. (2022) · consistentComparative Analysis of Liposuction and Conservative Treatment in Lipedema Patients: A Modified Body-Q Questionnaire Study — Aitzetmüller-Klietz et al. (2022) · consistentA 10-Year Retrospective before-and-after Study of Lipedema Surgery: Patient-Reported Lipedema-Associated Symptom Improvement after Multistage Liposuction — Kruppa et al. (2022) · consistent

Evidence (3)

Context (PECO)

Populationwomen with lipedema stages I–III
Conditionlipedema
Exposurelymph-sparing multistage liposuction
Comparatorpre-operative baseline
OutcomeCDT score, conservative therapy discontinuation, VAS symptoms
Scopeauto-ingested from Layer 1 surveillance

Answers these questions

Gaps & caveats

Auto-ingested single source; not yet human-reviewed.

Change log